All In Biotech

Drug Trial Radar · NCT00348764

ESGVS: Sclerotherapy With Lauromacrogol

Treatment of Greater Saphenous Vein (GSV) Insufficiency Using Echo-Guided Sclerotherapy With Lauromacrogol 400 Foam -Comparative Study of 3% Versus 1% Concentration.

Last checked: Nov 20, 2026Latest source record: Jul 6, 2006 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

150

Actual

Start

Mar 2004

Primary completion

Not stated

Study completion Dec 2006

Sponsor

Lead sponsor
University Hospital, GrenobleAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 6, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 25 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and the tolerance of echoguided sclerotherapy using Lauromacrogol 400 foam for the treatment of Great Saphenous Vein (GSV) insufficiency. A comparative study of 3% versus 1% Lauromacrogol 400 foam.

Conditions

  • Venous Insufficiency
  • Saphenous Vein

Interventions

  • lauromacrogolDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Removal of truncular GSV incompetence evaluated at 6 months by echo doppler: no persistence of "sus gonal" saphenous reflux > 1 second.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Center of Vascular Medecine - 7 rue Lesdiguières

    Grenoble, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.